Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

about

Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

Item

http://www.wikidata.org/entity/Q50086554

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Impact of RAS Mutations in Met ...... oes Site of Metastases Matter?

@en

Impact of RAS Mutations in Met ...... oes Site of Metastases Matter?

@nl

type

Item

label

Impact of RAS Mutations in Met ...... oes Site of Metastases Matter?

@en

Impact of RAS Mutations in Met ...... oes Site of Metastases Matter?

@nl

prefLabel

Impact of RAS Mutations in Met ...... oes Site of Metastases Matter?

@en

Impact of RAS Mutations in Met ...... oes Site of Metastases Matter?

@nl

P1476

Impact of RAS Mutations in Met ...... oes Site of Metastases Matter?

@en

P2093

BIG-RENAPE Working Group

http://www.w3.org/2001/XMLSchema#string

Bradford J Kim

http://www.w3.org/2001/XMLSchema#string

Claudius Conrad

http://www.w3.org/2001/XMLSchema#string

Diane Goere

http://www.w3.org/2001/XMLSchema#string

Frédéric Marchal

http://www.w3.org/2001/XMLSchema#string

Guillaume Passot

http://www.w3.org/2001/XMLSchema#string

Jean-Nicolas Vauthey

http://www.w3.org/2001/XMLSchema#string

Marc Pocard

http://www.w3.org/2001/XMLSchema#string

Michael J Overman

http://www.w3.org/2001/XMLSchema#string

Reza J Mehran

http://www.w3.org/2001/XMLSchema#string

P2860

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.

Association between KRAS mutation and lung metastasis in advanced colorectal cancer.

RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer

P2888

s10434-017-6141-7

P304

179-187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-017-6141-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Scott Kopetz

Olivier Glehen

P577

2017-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092347358

http://www.w3.org/2001/XMLSchema#string

P698

29071660

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer